Health-care companies rose amid drug development and deal activity.
Biotech concern Myovant Sciences rejected a buyout offer from its largest shareholder Sumitovant Biopharma, saying it undervalued Myovant.
Calithera Biosciences surged after the drug developer's experimental treatment for non-small cell lung cancer received Fast Track designation.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
10-03-22 1639ET
